It has been reported that 59% of melanomas, 18% of CRCs, 11% of gliomas, and 4% of lung adenocarcinomas and ovarian carcinomas contain BRAF mutations, which result in persistent activation of the MAPK/ERK pathway that leads to sustained proliferative signaling [37]. This evidence concerns the gene BRAF and lung adenocarcinoma.